Compare Baker Hughes Co (BKR) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs Moderna, Inc. — how do they compare? Baker Hughes Co trades at $57.78 (market cap $57.32B), while Moderna, Inc. trades at $67.37 (market cap $26.76B). The key difference: Baker Hughes Co is far larger — about 2.1× Moderna, Inc.'s market cap, and Baker Hughes Co pays a 1.59% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| BKR | MRNA | |
|---|---|---|
Market Cap | $57.32B | $26.76B |
Sector | Energy | Health |
52-Week High | $69.67 | $81.80 |
52-Week Low | $38.68 | $22.36 |
Enterprise Value | $58.72B | $22.85B |
Dividend Yield | 1.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baker Hughes (BKR) trades at $57.66, up 0.17% today, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a 66.7% buy rating from analysts, alongside a $74.09 price target, highlight positive momentum. The company secured key LNG and power infrastructure contracts, supporting growth in energy transition markets. Operating cash flow remains robust at $3.81B for 2025, though net income dipped slightly to $2.59B.
Outlook is positive driven by LNG expansion and AI-powered energy demand, but risks include oil price volatility and integration challenges from the Chart Industries acquisition. Valuation metrics like a P/E of 18.42 and ROE of 17.14% suggest reasonable pricing for growth prospects, though execution on new contracts is critical for sustained upside.
Moderna (MRNA) trades at $67.01, down 1.85% today, with a bullish technical signal from moving averages. The company continues to post net losses despite beating EPS estimates in recent quarters, with revenue declining from pandemic peaks. Recent news highlights pipeline expansion into oncology and autoimmune diseases, with an FDA decision on its mRNA flu vaccine expected by August 5, 2026.
While Moderna's pipeline diversification offers long-term growth potential, significant risks remain from persistent negative profitability and high valuation multiples. Analyst consensus is cautious with a $49 price target below current levels, suggesting limited near-term upside despite recent positive developments in vaccine approvals and strategic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
